Treatment 8 min
Head and neck cancer: chemotherapy, immunotherapy and radiotherapy, and how the regimen is chosen
Head and neck tumours: the role of HPV and EBV, chemoradiotherapy with cisplatin, cetuximab, immunotherapy with pembrolizumab and nivolumab, nasopharyngeal cancer, supportive care and questions for your doctor.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026
Head and neck cancer is a group of different tumours: of the oral cavity, oropharynx, nasopharynx, larynx, hypopharynx, nose and sinuses. What unites them is that most are squamous cell carcinomas and that treatment affects speech, swallowing, breathing and appearance. So the goal is not only to cure but also to preserve function.
In this article I explain which factors determine the choice of treatment, how chemoradiotherapy works, when surgery and immunotherapy are needed, what is special about nasopharyngeal cancer and how to cope with side effects. A practice example: stage IV nasopharyngeal cancer.
What the choice of treatment depends on
| Factor | Why it matters |
|---|---|
| Tumour site | It determines which functions are at risk and which methods are available |
| Stage | Early stages are treated with one method, advanced ones with a combination |
| Viruses | HPV (p16) in oropharyngeal cancer and Epstein–Barr virus in nasopharyngeal cancer change the course and approaches |
| PD-L1 | Needed to decide on immunotherapy in advanced disease (PD-L1) |
| General condition, nutrition, teeth, smoking | Affect tolerance and risks |
| Wish to preserve voice and swallowing | Determines the choice between surgery and an organ-preserving approach |
Diagnosis
- ENT examination with endoscopy and biopsy;
- MRI or CT of the neck, PET-CT in locally advanced disease (what PET-CT shows);
- in oropharyngeal cancer, p16/HPV testing;
- in nasopharyngeal cancer, Epstein–Barr virus DNA in the blood;
- a dental check before radiotherapy: diseased teeth are removed in advance, since doing it after radiotherapy is dangerous;
- assessment of nutrition and swallowing, consultation with a speech therapist.
If your report does not mention p16 or PD-L1, it is worth asking for them: how to read a pathology report.
Early stages
One method is usually enough: surgery or radiotherapy give comparable results. The choice is guided by functional consequences: what leaves the best chance of preserving voice, swallowing and appearance.
Locally advanced stages
The main options:
- Surgery, then radiotherapy (cisplatin is added when unfavourable features are found after surgery). For oral cavity tumours this is more often the first step.
- Definitive chemoradiotherapy: radiotherapy for about 7 weeks together with cisplatin. For tumours of the oropharynx, hypopharynx and larynx this is a common organ-preserving option.
- Induction chemotherapy (TPF regimen: docetaxel, cisplatin, 5-fluorouracil) before radiotherapy. It is used in selected patients, for example when the larynx must be preserved or tumours grow fast. The decision is made by a tumour board.
Cisplatin is the main drug that strengthens the effect of radiotherapy: platinum drugs. If cisplatin is contraindicated (kidney disease, hearing problems, severe neuropathy), carboplatin or cetuximab is used, but in trials in HPV-positive oropharyngeal cancer cetuximab with radiotherapy gave worse results than cisplatin with radiotherapy. So a substitution should be justified.
Immunotherapy before and after surgery
In the KEYNOTE-689 trial, in operable locally advanced head and neck cancer, adding pembrolizumab before and after surgery improved event-free survival in patients with PD-L1 CPS 1 or more. This is a new approach, and availability and indications differ between countries, so ask whether it was discussed for you: immunotherapy.
Nasopharyngeal cancer: special features
The nasopharynx lies deep, surgery is rarely possible, so radiotherapy is the basis of treatment. The tumour is usually sensitive to chemotherapy.
- In locally advanced disease the standard is radiotherapy with cisplatin.
- Before it, some trials used induction chemotherapy (gemcitabine with cisplatin or docetaxel regimens), which improved results in selected groups.
- After chemoradiotherapy, Epstein–Barr virus DNA in the blood is measured: a residual level may indicate recurrence risk.
- In metastatic disease or recurrence, chemotherapy (gemcitabine with cisplatin) is used with immunotherapy where it is registered.
A detailed review of a specific case: stage IV nasopharyngeal cancer.
Metastatic and recurrent head and neck cancer
When the disease has gone beyond what local treatment can deal with, systemic therapy is the basis.
- Pembrolizumab (alone or with platinum and 5-fluorouracil) in first line, especially with PD-L1 CPS 1 or more (KEYNOTE-048 trial).
- The EXTREME regimen: platinum, 5-fluorouracil and cetuximab when immunotherapy is unsuitable.
- Nivolumab after progression on platinum (CheckMate 141 trial).
- Other drugs and clinical trials: clinical trials.
Repeat surgery, re-irradiation or removal of single metastases are considered separately (oligometastases). At progression it is important to confirm it on scans: progression on treatment.
Side effects and how to reduce them
During radiotherapy:
- inflammation of the mouth and throat lining (mucositis): pain, ulcers, inability to eat. More: mucositis and stomatitis, stomatitis in chemotherapy;
- dry mouth and altered taste;
- skin burns in the neck area;
- weight loss.
On cisplatin:
- nausea and vomiting, so anti-sickness drugs are prescribed in advance (nausea in chemotherapy);
- kidney damage (so you need to drink plenty and have creatinine checked);
- hearing loss and ringing in the ears;
- numb fingers (neuropathy);
- low white cells (fever on chemotherapy).
Late effects of radiotherapy:
- chronic dry mouth and risk of tooth decay, so regular dentist visits are needed;
- limited mouth opening (trismus): daily exercises help;
- swelling of neck and face tissues (lymphoedema): special massage helps;
- reduced thyroid function: TSH is checked every few months;
- swallowing problems: work with a speech therapist helps.
Nutrition
Undernutrition is common in head and neck cancer and worsens tolerance of treatment. What helps:
- soft and pureed food, nutritional supplements;
- avoiding spicy, sour, hot and dry foods;
- with marked weight loss or inability to swallow, a feeding tube (nasogastric tube or gastrostomy) for the duration of treatment;
- a dietitian from the very start.
More: nutrition during chemotherapy. On pain: pain relief in cancer.
Smoking and alcohol
Continued smoking worsens the results of radiotherapy and raises the risk of second tumours. If you smoke, tell your doctor: help to quit is part of treatment and not a reproach.
Follow-up after treatment
Check-ups are more frequent in the first two years (examination, endoscopy, imaging when indicated) and less frequent later. The first PET-CT assessment is usually done a few months after radiotherapy. New pain, lumps in the neck, a change in voice or blood when coughing should be shown to a doctor without waiting for the next visit (recurrence after years).
What to ask your doctor
- Where exactly is the tumour and what is its stage?
- Were p16/HPV, EBV or PD-L1 tested?
- What options are there to preserve voice and swallowing?
- Why is surgery (or radiotherapy) recommended rather than another route?
- Is cisplatin suitable and what if not?
- Is immunotherapy needed now or in the future?
- How should teeth and nutrition be prepared and when to involve a speech therapist?
- How will we assess the result?
When to seek urgent help
- temperature of 38 °C or above;
- difficulty breathing, wheezing, noisy inhalation;
- bleeding from the mouth, nose or tumour site;
- inability to swallow water or saliva;
- sudden hearing loss, severe headache, vision problems;
- swelling and pain in one leg (see thrombosis in cancer).
Can I get a second opinion
Yes, especially when an extensive operation with loss of function is offered without discussing organ-preserving options, when p16/HPV, EBV or PD-L1 have not been tested, chemoradiotherapy or immunotherapy were not discussed, or the disease has returned. Prepare the pathology, MRI or CT, PET-CT, radiotherapy plans and summaries: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: head and neck tumours.
Sources
- Oropharyngeal Cancer Treatment (PDQ) — National Cancer Institute
- Nasopharyngeal Carcinoma Treatment (PDQ) — National Cancer Institute
- ESMO Clinical Practice Guidelines — ESMO
- Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
- Clinical guidelines (Russia) — Russian Ministry of Health
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
